Investing

AbbVie : ABBV

ABBV

Stock Data

$247.13

$0.95 (0.38%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Abbvie Inc. is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and selling a wide range of treatments. Its portfolio includes therapies for autoimmune diseases, various cancers, eye diseases, neurological disorders, and more. Notable products include Humira for autoimmune conditions, Skyrizi and Rinvoq for skin and joint diseases, and Imbruvica for blood cancers. AbbVie also offers products in aesthetics, women's health, and eye care. Founded in 2012 and based in North Chicago, Illinois, AbbVie collaborates with several biotech firms to advance its research in oncology and immunology.

Latest Activity

ABBVAbbVie

Jun 25, 7:45pm ET

New 52-week high$243.14+1.9% vs prior high · 2025-10-01

AbbVie hits a fresh 52-week high at $243.14, marking a new peak for the pharma giant navigating Humira biosimilar headwinds with its next-generation immunology pipeline.

ShareRead more

Biggest movers · At the closeJun 25, 4:10pm ET

Gainers

• SNDKSanDisk$2,302.65+20.3%
• GPROGoPro$0.76+6.7%
• QCOMQualcomm$206.73+4.7%
• TEMTempus AI$54.29+4.5%
• ABBVAbbVie$243.22+3.5%

Losers

• AMCAMC Entertainment$1.83-8.8%
• DUOLDuolingo$121.12-8.3%
• FUBOfuboTV$8.05-8.0%

SanDisk surged 20% as memory demand hits record levels, a stunning reversal from retail stalwarts AMC and Duolingo both tanking over 8% in the same session.

ShareRead more

ABBVAbbVie

Regular session

Jun 22, 12:20pm ET

$231.66

+3.62%open $223.58

Defensive pharma gaining as investors pivot away from tech weakness, lifting the stock 3.62% intraday.

ShareRead more

All AbbVie Articles

612 Articles

Joel South | 6 hours ago

The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into…

Vandita Jadeja | Jul 10, 2026 at 11:30 AM EDT

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which…

Joel South | Jul 8, 2026 at 11:31 AM EDT

JEPI vs. JEPQ: Which Is the Better Buy in July?

The battle between JPMorgan’s two flagship covered-call income ETFs comes down to a simple trade-off: JPMorgan Equity Premium Income ETF…

Joel South | Jul 7, 2026 at 8:00 AM EDT

3 Dividend Aristocrats to Buy in July

Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of…

Omor Ibne Ehsan | Jul 6, 2026 at 3:05 PM EDT

A 2.86% Yield, 0.08% Fee, and 75 Stocks: Is HDV the Anti-Hype ETF?

Dividend funds pulled in $24.1 billion in the first quarter of 2026, their strongest opening quarter in four years, and…

John Seetoo | Jul 5, 2026 at 1:47 PM EDT

Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds…

David Beren | Jul 3, 2026 at 4:22 PM EDT

Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.

The average Social Security retirement check reached $2,081 per month as of April 2026, according to the Social Security Administration’s…

Joel South | Jul 2, 2026 at 8:00 AM EDT

3 Dividend Stocks to Buy Hand Over Fist in July

Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise…

Marc Guberti | Jul 1, 2026 at 7:55 AM EDT

MTUM Investors: Watch Micron’s Weight at the November Reconstitution

The iShares MSCI USA Momentum Factor ETF (NYSEARCA:MTUM) has run hard this year, climbing 30% year to date and 38%…

Drew Wood | Jun 26, 2026 at 7:03 AM EDT

The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

What does retirement look like for someone who genuinely has no desire to leave home? No snowbird condo in Florida.…

Trey Thoelcke | Jun 25, 2026 at 8:15 AM EDT

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have…

Alex Sirois | Jun 24, 2026 at 4:33 PM EDT

Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut

I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it…

Drew Wood | Jun 24, 2026 at 11:38 AM EDT

The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari

Most retirees shop for dividend portfolios the same way people shop for cars: they focus on what they get today.…

Alex Sirois | Jun 24, 2026 at 10:02 AM EDT

64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital

At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at…

Trey Thoelcke | Jun 24, 2026 at 7:55 AM EDT

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three…